Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2022 Jan 6;21(1):136–142. doi: 10.1016/j.cgh.2021.12.047

Table 1:

Comparison between derivation and validation cohorts

Demographics Derivation cohort
(N=398)
Validation Cohort
(N=94)
P value
Age (Mean(SD)) 59±8 56±7 0.0009
Male sex N (%) 335(84.1%) 54(55%) <0.0001
Education (Median (IQR)) 13 (12, 14) 13 (12, 15) 0.56
CHE on PHES N (%) 201(50.5%) 43(44%) 0.23
MELD score (Mean(SD)) 12.5 (5.7) 12.4 (6.0) 0.88
Rifaximin N (%) 152(38%) 28(30%) 0.13
Prior Overt HE N (%) 164(41%) 32(32.2%) 0.11
EncephalApp (Mean (SD)) seconds
Total Off Time 85.5(74.5,101) 78(65,93) 0.0002
Total On Time 103(89,125) 94(78,108) 0.0003
Total OffTime+OnTime 189(163,225) 172 (147,201) 0.0002

CHE: covert hepatic encephalopathy, PHES: psychometric hepatic encephalopathy score, HE: hepatic encephalopathy; all patients with prior HE were on lactulose.